Evotec Extends Research Collaboration With Boehringer Ingelheim

Evotec has extended the research collaboration with Boehringer Ingelheim for a further 4 years, based on the success to date in the areas of CNS, inflammation, cardiometabolic and respiratory diseases the scope of the collaboration has been expanded to also include oncology targets. Over the term of the extension Evotec is expected to receive research funding of around E15m plus success milestones and royalties.

In 2004, Evotec and Boehringer Ingelheim have entered into a multiyear drug discovery collaboration to jointly identify and develop preclinical development candidates for the treatment of various diseases.

As per the terms of the agreement, Boehringer Ingelheim has full ownership and global responsibility for clinical development, manufacturing and commercialisation of the compounds identified.

In addition, Evotec receives ongoing research payments and preclinical milestones. Furthermore, the contract provides substantial long-term upside for Evotec through potential payments for successful milestone achievements during clinical development and royalties when new drugs reach the market.

Wolfgang Rettig, corporate senior vice president of research at Boehringer Ingelheim, said: “Evotec has continually demonstrated exceptional scientific expertise in support of our research. We are very pleased to be able to continue our collaboration with Evotec and expand it into new areas of research and have no doubt that they will continue to assist us in achieving our drug discovery goals.”